Anaeropharma Science
Latest round
- Series H
Last raised
- Jul 2017
Total raised
- $12M
Investors
- 5
About Anaeropharma Science
Founded in 2004 and based in Tokyo, Japan, Anaeropharma Science, Inc. operates as a biopharmaceutical company that develops therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology. In November 2022, Anaeropharma Science, Inc. Anaeropharma’s offers a proprietary platform, i-DPS (intelligent Drug Delivery System), that enables localized drug activation. Its lead technology, i-DPS, utilizes recombinant Bifidobacterium to selectively colonize hypoxic tumor regions. Once localized, the bacteria express enzymes that convert systemically administered prodrugs into active cytotoxic agents directly within the tumor microenvironment. This approach minimizes systemic toxicity and enhances therapeutic precision. The platform has potential applications in oncology and other diseases characterized by hypoxia.
Who invested in Anaeropharma Science
5 investors across 1 round
See all investors in Anaeropharma Science
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series H
Jul 5, 2017
Amount
$12M
Investors
Questions about Anaeropharma Science
Who invested in Anaeropharma Science?
Anaeropharma Science has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anaeropharma Science raised?
Anaeropharma Science has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Anaeropharma Science last raise money?
Anaeropharma Science's most recent round on record is a Series H, in Jul 2017.
What does Anaeropharma Science do?
Founded in 2004 and based in Tokyo, Japan, Anaeropharma Science, Inc.
Where is Anaeropharma Science headquartered?
Anaeropharma Science is headquartered in Tokyo, Japan.
Which VCs invest in companies like Anaeropharma Science?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Anaeropharma Science's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series H
Raising like Anaeropharma Science? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.